ST 857

Drug Profile

ST 857

Latest Information Update: 14 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sigma-tau SpA
  • Class Antidementias; Basic amino acids; Diamino amino acids; Essential amino acids; Neuroprotectants; Small molecules
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cognition disorders

Most Recent Events

  • 25 Jun 2001 No-Development-Reported for Cognition disorders in Italy (Unknown route)
  • 25 May 1995 Preclinical development for Cognition disorders in Italy (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top